The Impact of Nicotinic Receptors on Drug Therapies in Dentistry
Abstract
Nicotinic receptors are seen in the central nervous system ( CNS ), Peripheral nervous system ,( PNS ) and neuro muscular junctions, making them pivotal in dental procedures that involve pain management, anesthesia and muscle relaxation. Their interaction with drugs can impact the efficacy in a significant manner and safety of dental treatments. In dentistry, local anesthetics are frequently used to create a momentary numbness and lessen pain during procedures like root canal therapy and tooth extractions. These agents primarily perform by blocking sodium channels, thereby stopping nerve conduction. During certain dental procedures namely orthodontic adjustments or temporo mandibular joint ( TMJ ) treatments, muscle relaxants may be administered to inhibit muscle spasms and improve manipulation. Dentist must consider the interaction between muscle relaxants and nicotinic receptors to ensure optimal outcomes ND minimize adverse effects. Pain management is an important aspect of dentistry, particularly for procedures that may cause discomfort or post_ operative pain. Dentists need to evaluate individual patient factors along with nicotine exposure as well as receptor sensitivity. Chronic nicotine exposure can lead to receptor desensitization and alterations in receptor density, potentially influencing the response to pharmacological interventions in dentistry. Incorporating knowledge of nicotinic receptors and their influence on drug therapy is responsible for dental practitioners to deliver safe and effective care. Finally it is concluded that nicotinic receptors play an important role in mediating the effects of drugs generally used in dentistry along with local anesthetics, muscle relaxants and analgesics.
Full Text:
PDFReferences
Sofuoglu M, Mooney M. Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs. 2009 Nov;23(11):939-52. [PMC free article] [PubMed]
Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006 Jan;104(1):158-69. [PubMed]
Papke RL. Merging old and new perspectives on nicotinic acetylcholine receptors. Biochem Pharmacol. 2014 May 01;89(1):1-11. [PMC free article] [PubMed]
Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov. 2014 Jul;13(7):549-60. [PMC free article] [PubMed]
Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H, Zhang YW. M1 muscarinic acetylcholine receptor in Alzheimer's disease. Neurosci Bull. 2014 Apr;30(2):295-307. [PMC free article] [PubMed]
Shapiro RA, Tietje KM, Subers EM, Scherer NM, Habecker BA, Nathanson NM. Regulation of muscarinic acetylcholine receptor function in cardiac cells and in cells expressing cloned receptor genes. Trends Pharmacol Sci. 1989 Dec;Suppl:43-6. [PubMed]
Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002 Jul;136(5):641-3. [PMC free article] [PubMed]
Abreu-Villaça Y, Filgueiras CC, Manhães AC. Developmental aspects of the cholinergic system. Behav Brain Res. 2011 Aug 10;221(2):367-78. [PubMed]
Wehrwein EA, Orer HS, Barman SM. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. Compr Physiol. 2016 Jun 13;6(3):1239-78. [PubMed]
Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A, Zouridakis M, Tzartos SJ. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J. 2007 Aug;274(15):3799-845. [PubMed]
Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res. 2001 Sep;44(3):161-82. [PubMed]
Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci. 2001 Jul 15;21(14):5239-50. [PMC free article] [PubMed]
Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, Haga T, Kobayashi T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature. 2012 Jan 25;482(7386):547-51. [PMC free article] [PubMed]
Caulfield MP. Muscarinic receptors--characterization, coupling and function. Pharmacol Ther. 1993 Jun;58(3):319-79. [PubMed]
Barrantes FJ. The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents. Neurochem Res. 1997 Apr;22(4):391-400. [PubMed]
Refbacks
- There are currently no refbacks.